C92-C00

Acute myeloblastic leukemia not having achieved remission

## Overview of Acute Myeloblastic Leukemia (AML) Not Having Achieved Remission Acute Myeloblastic Leukemia (AML), also known as Acute Myelogenous Leukemia, is a heterogeneous group of aggressive hematologic malignancies characterized by the rapid proliferation of abnormal myeloid progenitor cells (blasts) in the bone marrow, peripheral blood, and other tissues. These malignant cells interfere with the production of normal blood cells, leading to bone marrow failure. The specific code C92.00, "Acute myeloblastic leukemia not having achieved remission," indicates a clinical state where a patient diagnosed with AML has not yet responded to initial induction therapy sufficiently to achieve a state of complete remission, or has relapsed from a previous remission. ### Pathophysiology AML originates from somatic mutations in hematopoietic stem and progenitor cells. These mutations lead to uncontrolled proliferation, impaired differentiation, and increased survival of myeloid blasts. Common genetic alterations involve genes encoding transcription factors (e.g., RUNX1, CBFB, PML-RARA), epigenetic regulators (e.g., DNMT3A, TET2, IDH1/2), tumor suppressors (e.g., TP53), and signaling pathways (e.g., FLT3, KIT). The accumulation of these immature blasts in the bone marrow replaces normal hematopoietic cells, leading to cytopenias: anemia (due to lack of red blood cells), thrombocytopenia (due to lack of platelets), and neutropenia (due to lack of mature neutrophils). The blasts can also infiltrate extramedullary sites such as the liver, spleen, lymph nodes, central nervous system, and skin, causing organomegaly or specific localized symptoms. ### Clinical Presentation The clinical presentation of AML is often acute and related to bone marrow failure and organ infiltration. Patients typically present with symptoms of anemia (fatigue, pallor, dyspnea), thrombocytopenia (easy bruising, petechiae, epistaxis, gingival bleeding), and neutropenia (recurrent or severe infections, fever). Other common symptoms include unexplained weight loss, night sweats, bone or joint pain, and anorexia. Infiltrative symptoms may include gum hypertrophy, skin lesions (leukemia cutis), lymphadenopathy, hepatosplenomegaly, and, rarely, symptoms of central nervous system involvement (e.g., headache, cranial nerve palsies) or myeloid sarcoma (chloroma). When a patient is described as "not having achieved remission" (C92.00), it implies that despite initial treatment attempts, the disease persists with detectable blasts (typically >5% in the bone marrow) and/or continued evidence of bone marrow failure. This could be due to primary refractory disease (failure to achieve remission after initial induction chemotherapy) or early relapse after a brief remission. ### Diagnostic Criteria Diagnosis of AML requires morphologic assessment, immunophenotyping, cytogenetics, and molecular genetic testing of bone marrow and peripheral blood samples. Key diagnostic criteria include: * Presence of ≥ 20% myeloid blasts in the bone marrow or peripheral blood. (Exceptions include AML with recurrent genetic abnormalities like t(8;21), inv(16), or t(15;17), where the diagnosis can be made even with <20% blasts if the characteristic genetic abnormality is present). * Exclusion of other acute leukemias or myelodysplastic syndromes. * Immunophenotyping by flow cytometry is crucial to confirm myeloid lineage (e.g., CD13, CD33, CD117, MPO positivity) and identify specific subtypes. * Cytogenetic and molecular studies identify prognostic markers (e.g., NPM1, FLT3-ITD, CEBPA mutations, complex karyotype, monosomy 5/7) that guide treatment intensity and risk stratification. For C92.00, the diagnosis of AML would have already been established, and the

Clinical Symptoms

Fatigue
Pallor
Dyspnea
Easy bruising
Petechiae
Epistaxis
Gingival bleeding
Recurrent infections
Fever
Weight loss
Night sweats
Bone pain
Joint pain
Anorexia
Gum hypertrophy
Skin lesions (leukemia cutis)
Lymphadenopathy
Hepatosplenomegaly
Headache
Cranial nerve palsies
Myeloid sarcoma (chloroma)

Common Causes

Somatic mutations in hematopoietic stem and progenitor cells (e.g., FLT3, NPM1, DNMT3A, TET2, IDH1/2, TP53, RUNX1, CEBPA)
Prior exposure to chemotherapy (e.g., alkylating agents, topoisomerase II inhibitors)
Prior exposure to radiation therapy
Exposure to certain industrial chemicals (e.g., benzene)
Pre-existing hematologic disorders (e.g., myelodysplastic syndromes, myeloproliferative neoplasms)
Certain genetic syndromes (e.g., Down syndrome, Fanconi anemia, Bloom syndrome, Ataxia-telangiectasia, Li-Fraumeni syndrome, Neurofibromatosis type 1)
Family history of AML (rare)
Advanced age

Documentation & Coding Tips

Always specify the type of Acute Myeloid Leukemia (AML) and whether remission has been achieved or not. Distinguish between initial diagnosis, relapse, or refractory disease.

Example: Patient is a 58 y/o male with newly diagnosed AML, M4 subtype (acute myelomonocytic leukemia), not yet having achieved remission despite induction chemotherapy with 7+3 regimen. Current bone marrow biopsy shows 35% blasts. ECOG PS 2 due to profound fatigue and anemia (Hb 7.2). Plan: Begin consolidation therapy pending count recovery. This patient has a documented history of myelodysplastic syndrome (MDS) prior to AML transformation, which is an additional HCC condition affecting risk adjustment.

Billing Focus: Specificity of AML subtype (M4), clear statement of 'not having achieved remission', and identification of associated conditions like MDS for higher reimbursement.

Document all clinical manifestations, complications, and treatments related to AML and its current status, including bone marrow findings, lab values, and performance status.

Example: Acute Myeloid Leukemia, not having achieved remission. Patient presents with febrile neutropenia (ANC 0.1), temperature 38.8C. Peripheral smear shows circulating blasts. Bone marrow aspirate confirms persistent disease with 28% blasts. Patient is critically ill, requiring broad-spectrum IV antibiotics (Meropenem, Vancomycin) and aggressive supportive care including PRBC and platelet transfusions. This status significantly impacts resource utilization and overall patient severity.

Billing Focus: Detailed documentation of complications like febrile neutropenia (T80.211A) and resource utilization (antibiotics, transfusions) supports higher E/M levels and appropriate DRG assignment.

Clearly differentiate between initial induction therapy, consolidation, or salvage therapy when the patient has not achieved remission.

Example: Patient continues to have acute myeloblastic leukemia not having achieved remission. This visit is for Cycle 2 of salvage chemotherapy with FLAG-IDA regimen following failure of initial induction therapy. Patient tolerated Cycle 1 with expected pancytopenia requiring transfusions. This refractory status indicates a highly complex and resource-intensive patient management.

Billing Focus: Specification of 'salvage chemotherapy' after 'failure of initial induction therapy' clarifies the complexity of the patient's condition and the intensity of ongoing treatment, justifying higher E/M codes and potentially specific drug administration codes.

When describing symptoms, link them directly to the active AML and its 'not in remission' status, particularly for anemia, thrombocytopenia, and neutropenia.

Example: AML, not having achieved remission, presenting with severe fatigue due to symptomatic anemia (Hgb 6.8 g/dL), requiring transfusion. Also noted petechiae secondary to severe thrombocytopenia (platelets 8,000/uL), managed with platelet transfusions. Bruising on bilateral upper extremities also present. These are direct manifestations of active bone marrow infiltration by leukemic cells. Patient requires strict isolation precautions due to profound neutropenia (ANC 0.05).

Billing Focus: Connecting symptoms directly to the underlying active leukemia justifies medical necessity for extensive monitoring and treatments. Specificity for 'symptomatic anemia' (D64.9), 'severe thrombocytopenia' (D69.49), and 'profound neutropenia' (D70.9) linked to C92.00 enhances billing accuracy.

Document diagnostic procedures and their findings with clear interpretation to support the 'not having achieved remission' status.

Example: AML, not having achieved remission. Bone marrow biopsy and aspirate performed on [date] demonstrated hypercellular marrow with 40% myeloblasts, consistent with persistent disease. Cytogenetics pending. Flow cytometry showed persistent aberrant myeloid blast population. Peripheral blood smear reveals leukocytosis with 60% blasts. These findings confirm failure to achieve complete remission.

Billing Focus: Explicitly stating the findings ('40% myeloblasts', 'persistent aberrant myeloid blast population') and their interpretation ('consistent with persistent disease', 'failure to achieve complete remission') supports the C92.00 diagnosis and the medical necessity for further interventions.

Relevant CPT Codes

96401 - Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic
Used for administration of certain chemotherapy drugs, though intravenous is more common for induction/consolidation.
96413 - Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance
Commonly used for initial or single agent chemotherapy infusions in AML, like Cytarabine or Daunorubicin.
96416 - Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)
Many AML chemotherapy regimens involve infusions lasting several hours or continuously over days (e.g., high-dose Cytarabine).
38220 - Diagnostic bone marrow; aspiration(s)
Essential for initial diagnosis, assessing remission status, and monitoring disease progression/relapse in AML.
38221 - Diagnostic bone marrow; biopsy(ies)
Often performed concurrently with bone marrow aspiration for comprehensive assessment of marrow cellularity and architecture.
88182 - Flow cytometry, cell cycle or DNA analysis
Used to identify blast populations, immunophenotype, and assess minimal residual disease (MRD) in AML.
88237 - Chromosome analysis; count 20-25 cells, 1-2 karyograms, with banding
Cytogenetic analysis is crucial for AML prognostication and classification (e.g., t(8;21), inv(16), del(5q)).
81245 - FLT3 gene analysis; internal tandem duplication (ITD) variants
FLT3-ITD mutations are common in AML and have prognostic and therapeutic implications (e.g., use of FLT3 inhibitors).
36556 - Insertion of non-tunneled centrally inserted central venous catheter; without subcutaneous port or pump; age 5 years or older
Many AML patients require central venous access for prolonged chemotherapy infusions, frequent blood draws, and supportive care.
36573 - Replacement, without placement of stylet or guide wire, of non-tunneled centrally inserted central venous catheter, through same venous access site
Central lines may need replacement due to infection or malfunction, a common occurrence in immunocompromised AML patients.
99223 - Initial hospital inpatient or observation care, per day, for the evaluation and management of a patient, which requires a medically appropriate history and/or examination and high complexity medical decision making. (Level 3)
AML patients not in remission, especially during induction or complications, require high-complexity medical decision-making.
99233 - Subsequent hospital inpatient or observation care, per day, for the evaluation and management of a patient, which requires a medically appropriate history and/or examination and high complexity medical decision making. (Level 3)
Daily rounds for AML patients undergoing active treatment or managing severe complications often involve high complexity.